RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $203
Revolution Medicines
Revolution Medicines RVMD | 0.00 |
RBC Capital analyst Leonid Timashev maintains Revolution Medicines (NASDAQ:
RVMD) with a Outperform and raises the price target from $182 to $203.
